Who has been buying GFC Life Science stock?

2 distinct insiders have filed 12 disclosed insider purchases in GFC Life Science (388610), most recently on 2026-07-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does GFC Life Science have?

GFC Life Science has 12 buy-side and 0 sell-side disclosures on record, covering ₩152M ($105K) in total reported value, spanning 2025-11-06 to 2026-07-15.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

GFC Life Science 388610

Company

지에프씨생명과학GFC Life Science

Insiders

Buys

Total Value

₩152M ($105K)

Avg Return

-0.91%

Last Filing

2026-07-15

GFC Life Science (388610) has 12 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩152M ($105K) in reported transaction value. The earliest filing StockDrifts holds for GFC Life Science is dated 2025-11-06; the most recent is 2026-07-15. Across these filings the average return since disclosure is -0.91%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-09-15	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	135	₩5,840	-1.2%	₩775K ($538)
2026-09-14	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	408	₩5,850	-1.4%	₩2M ($2K)
2026-09-09	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	527	₩5,340	+9.4%	₩3M ($2K)
2026-09-08	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	30	₩5,060	+15.4%	₩158K ($110)
2026-09-04	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	38	₩5,230	+0.0%	₩199K ($138)
2026-09-03	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	561	₩5,200	+0.6%	₩3M ($2K)
2026-09-02	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	415	₩5,230	+0.0%	₩2M ($2K)
2026-09-01	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	990	₩5,350	-2.2%	₩5M ($4K)
2026-08-27	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	478	₩5,170	+2.9%	₩3M ($2K)
2026-08-26	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.4K	₩5,460	-2.6%	₩8M ($5K)
2026-08-25	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	386	₩5,470	-2.7%	₩2M ($1K)
2026-08-18	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	249	-	-	-
2026-08-14	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	590	-	-	-
2026-08-13	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	788	-	-	-
2026-08-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	94	₩6,110	+4.9%	₩565K ($392)
2026-08-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	229	₩6,020	+1.5%	₩1M ($938)
2026-08-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	240	₩6,020	+6.5%	₩1M ($1K)
2026-08-05	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.4K	₩5,980	+2.2%	₩8M ($6K)
2026-08-05	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	163	₩5,980	+7.2%	₩982K ($682)
2026-08-04	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	553	₩5,900	+3.6%	₩3M ($2K)
2026-08-03	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	2.3K	₩5,650	+8.1%	₩12M ($8K)
2026-07-31	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	2.8K	₩5,410	+0.0%	₩14M ($10K)
2026-07-23	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	836	₩6,000	-2.0%	₩5M ($3K)
2026-07-22	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.6K	₩5,800	+1.4%	₩10M ($7K)
2026-07-21	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	999	₩5,800	+1.4%	₩6M ($4K)
2026-07-20	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	370	₩5,800	+1.4%	₩2M ($2K)
2026-07-16	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	4.7K	₩6,040	-2.6%	₩26M ($18K)
2026-07-15	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	4.4K	₩5,900	+2.4%	₩24M ($17K)
2026-07-14	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.0K	₩5,620	+7.5%	₩5M ($4K)
2026-07-13	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	3.7K	₩5,570	+8.4%	₩17M ($12K)
2026-06-16	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	59	₩6,230	-7.4%	₩331K ($230)
2026-05-18	BUY	주식매수선택권	이동환 Donghwan Lee	Managing Director	21.7K	₩8,300	-10.4%	₩180M ($125K)
2026-04-10	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	417	₩9,390	+7.6%	₩4M ($3K)
2026-04-09	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.9K	₩9,240	+9.3%	₩17M ($12K)
2026-04-08	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	3.3K	₩9,530	+6.0%	₩32M ($22K)
2026-04-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	961	₩9,490	+6.4%	₩9M ($6K)
2026-04-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.2K	₩9,500	+6.3%	₩11M ($8K)
2026-04-01	BUY	Market Buy	민진우 Jinwoo Min	Internal director	100	₩9,490	+6.4%	₩949K ($659)
2026-03-26	BUY	신규선임	민진우 Jinwoo Min	Internal director	20.8K	₩10,070	+1.2%	₩210M ($146K)
2025-11-10	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	23	₩15,060	-24.2%	₩346K ($241)
2025-11-09	SELL	특별관계해소	표형배 Hyeongbae Pyo	Clinical Division Representative	-7.5K	₩15,060	+24.2%	₩113M ($78K)
2025-11-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	739	₩14,760	-22.7%	₩11M ($8K)
2025-11-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.3K	₩15,080	-24.3%	₩20M ($14K)

Frequently asked questions

Who has been buying GFC Life Science stock?: 2 distinct insiders have filed 12 disclosed insider purchases in GFC Life Science (388610), most recently on 2026-07-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does GFC Life Science have?: GFC Life Science has 12 buy-side and 0 sell-side disclosures on record, covering ₩152M ($105K) in total reported value, spanning 2025-11-06 to 2026-07-15.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.